Review on the updates in the management of hypertension (original) (raw)

Globally, hypertension is the leading cause of cardiovascular illness and death, particularly in low-and middle-income nations. Despite the availability of safe, well-tolerated, and cost-effective blood pressure (BP)-lowering treatments, 14% of adults with hypertension have BP 140/90 mm Hg. In compliance with the World Health Organization's Handbook for Guideline Development, we present new hypertension treatment guidelines. Using the Grading of Recommendations, Assessment, Development, and Evaluations methodology, overviews of reviews of the evidence were undertaken and summary tables were generated. In these guidelines, the World Health Organization provides the most recent and relevant evidence-based recommendations for the pharmacological treatment of individuals without hypertension who are not pregnant. The recommendations apply to adults with a confirmed diagnosis of hypertension who have received counselling on lifestyle adjustment. The recommendations include the blood pressure (BP) threshold for initiating pharmaceutical therapy, BP treatment targets, intervals for follow-up visits, and the optimal utilisation of health care professionals in the management of hypertension. The guidelines include guidance about the selection of monotherapy or dual therapy, treatment with single-pill combination drugs, and the application of treatment algorithms for the management of hypertension. The strength of the recommendations was determined by the quality of the underlying evidence, the tradeoffs between desirable and undesirable effects, the patient's values, resource considerations, and cost-effectiveness, health equity, acceptability, and feasibility considerations for various treatment options. The purpose of the guideline is to promote standardised approaches to the pharmacological treatment and management of hypertension, which, if widely adopted, will raise the global hypertension control rate.